The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction?

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 4, 2008, Pages 344.e1-344.e7

  Scifres, Christina M ^a   Macones, George A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

inherited thrombophilia; pregnancy; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTROGEN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; ARTICLE; CLINICAL PRACTICE; DISEASE ASSOCIATION; FAMILY STUDY; GENE MUTATION; HEALTH INSURANCE; HUMAN; INCIDENCE; LOW DRUG DOSE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; SCREENING TEST; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 52949150778     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.051     Document Type: Article

References (67)

1. Kujovich J.L. Hormones and pregnancy: Thromboembolic risks for women. Br J Haematol 126 (2004) 443-454
2. Chang J., Elam-Evans L.D., Berg C.J., et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 52 (2003) 1-8
3. Walker M.C., Garner P.R., Keely E.J., Rock G.A., and Reis M.D. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 177 (1997) 162-169
4. Kruithof E.K., Tran-Thang C., Gudinchet A., et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 69 (1987) 460-466
5. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 346 (1995) 1133-1134
6. Lee D.H., Henderson P.A., and Blajchman M.A. Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 155 (1996) 285-289
7. Rosendaal F.R., Doggen C.J., Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79 (1998) 706-708
8. Dykes A.C., et al. A study of protein S antigen levels in 3788 healthy volunteers: Influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 113 (2001) 636-641
9. Miletich J., Sherman L., and Broze Jr. G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317 (1987) 991-996
10. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73 (1995) 87-93
11. Odegard O.R., and Abildgaard U. Antithrombin III: Critical review of assay methods. Significance of variations in health and disease. Haemostasis 7 (1978) 127-134
12. Meade T.W., et al. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 74 (1990) 77-81
13. Tait R.C., Walker I.D., Perry D.J., et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87 (1994) 106-112
14. Makris M., Rosendaal F.R., and Preston F.E. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 740 (1997) 9-15
15. Mateo J., Oliver A., Borrell M., Sala N., and Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 77 (1997) 444-451
16. Ridker P.M., Goldhaber S.Z., and Glynn R.J. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 349 (2003) 2164-2167 author reply 2164-7
17. Schulman S., Wåhlander K., Lundström T., et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
18. Koster T., Rosendaal F.R., de Ronde H., Briët E., Vandenbroucke J.P., and Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
19. Ridker P.M., Miletich J.P., Stampfer M.J., Goldhaber S.Z., Lindpaintner K., and Hennekens C.H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92 (1995) 2800-2802
20. Margaglione M., Brancaccio V., Giuliani N., et al. Increased risk for venous thrombosis in carriers of the prothrombin G->A20210 gene variant. Ann Intern Med 129 (1998) 89-93
21. Emmerich J., Rosendaal F.R., Catteno M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 86 (2001) 809-816
22. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342 (2000) 374-380
23. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., and Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 (2002) 791-795
24. Guttormsen A.B., Ueland P.M., Nesthus I., et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest 98 (1996) 2174-2183
25. Kluijtmans L.A., Young I.S., Boreham C.A., et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101 (2003) 2483-2488
26. Ray J.G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 158 (1998) 2101-2106
27. den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B., and Bos G.M. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemost 80 (1998) 874-877
28. Tsai A.W., Cushman M., Tsai M.Y., et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 72 (2003) 192-200
29. Bezemer I.D., Doggen C.J., Vos H.L., and Rosendaal F.R. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: Results from the MEGA study. Arch Intern Med 167 (2007) 497-501
30. den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 109 (2007) 139-144
31. Bates S.M., Greer I.A., Hirsh J., and Ginsberg J.S. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl 3 (2004) 627S-644S
32. Tengborn L., Bergqvist D., Mätzsch T., Bergqvist A., and Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 160 (1989) 90-94
33. Badaracco M.A., and Vessey M.P. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J 1 (1974) 215-217
34. Howell R., Fidler J., Letsky E., and de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: A controlled trial. Br J Obstet Gynaecol 90 (1983) 1124-1128
35. Lao T.T., de Swiet M., Letsky S.E., and Walters B.N. Prophylaxis of thromboembolism in pregnancy: An alternative. Br J Obstet Gynaecol 92 (1985) 202-206
36. de Swiet M., Floyd E., and Letsky E. Low risk of recurrent thromboembolism in pregnancy. Br J Hosp Med 38 (1987) 264
37. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 343 (2000) 1439-1444
38. Barbour L.A. ACOG practice bulletin. Thrombembolism in pregnancy. Int J Gynaecol Obstet 75 (2001) 203-212
39. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
40. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., and Melton III L.J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 160 (2000) 761-768
41. Schulman S., Rhedin A.S., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332 (1995) 1661-1665
42. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 340 (1992) 873-876
43. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., and Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332 (1995) 912-917
44. Simioni P., Prandoni P., Lensing A.W., et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96 (2000) 3329-3333
45. Simioni P., Prandoni P., Lensing A.W., et al. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 336 (1997) 399-403
46. Miles J.S., Miletich J.P., Goldhaber S.Z., Hennekens C.H., and Ridker P.M. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37 (2001) 215-218
47. Eichinger S., Minar E., Hirschl M., et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 81 (1999) 14-17
48. Eichinger S., Pabinger I., Stümpflen A., et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77 (1997) 624-628
49. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
50. Lindmarker P., Schulman S., Sten-Linder M., Wiman B., Egberg N., and Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 81 (1999) 684-689
51. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
52. Margaglione M., D'Andrea G., Colaizzo D., et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 82 (1999) 1583-1587
53. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 113 (2001) 630-635
54. Ho W.K., Hankey G.J., Quinlan D.J., and Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: A systematic review. Arch Intern Med 166 (2006) 729-736
55. Buller H.R., Agnelli A., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl 3 (2004) 401S-428S
56. Kearon C. Long term management of patients after venous thromboembolism. Circulation 110 Suppl 1 (2004) 10-18
57. Ost D., Tepper J., Mihara H., et al. Duration of anticoagulation following VTE: A meta-analysis. JAMA 294 (2005) 706
58. Makris M., Preston F.E., Beauchamp N.J., et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 78 (1997) 1426-1429
59. Koeleman B.P., Reitsma P.H., and Bertina R.M. Familial thrombophilia: A complex genetic disorder. Semin Hematol 34 (1997) 256-264
60. Meinardi J.R., Middeldorp S., de Kam P.J., et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 116 (2002) 625-631
61. Sarasin F.P., and Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. Br Med J 316 (1998) 95-99
62. Couturaud F., Kearon C., Leroyer C., et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 96 (2006) 744-749
63. Coppens M., van de Poel M.H., Bank I., et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 108 (2006) 2604-2607
64. Langlois N.J., and Wells P.S. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: A systematic review. Thromb Haemost 90 (2003) 17-26
65. Sanson B., Simioni P., Tormene D., et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 94 (1999) 3702-3706
66. Zotz R., Gerhardt A., and Sharf R. Inherited thrombophilia and gestational venous thromboembolism. Best Prac Res Clin Haematol 16 (2003) 243-259
67. Simoni P., Tormene D., Spiezia L., et al. Inherited thrombophilia and venous thromboembolism. Sem Thromb Hemost 32 (2006) 700-708